COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn PVP-IPVP-I FLVFLV REGNR2 LY-CoVLY RemdesivirRMD
Vitamin D study #65 of 71
2/1 Analysis of outcomes based on serum levels
Patchen et al., medRxiv, doi:10.1101/2021.01.29.21250759 (Preprint)
Genetically predicted serum vitamin D and COVID-19: a Mendelian randomization study
Source   PDF   Share   Tweet
UK Biobank Mendelian randomization study not finding significant differences in COVID-19 risk. The number of people predicted to have vitamin D deficiency does not appear to be provided.
For some background on Mendelian randomization studies and their limitations see [1].

Patchen et al., 2/1/2021, retrospective, United Kingdom, Europe, preprint, 5 authors.
risk of COVID-19 severe case, 2.0% lower, RR 0.98, p = 0.11, odds ratio converted to relative risk, >50nmol/L, baseline risk approximated with overall risk.
risk of hospitalization, no change, RR 1.00, p = 1.00, odds ratio converted to relative risk, >50nmol/L, baseline risk approximated with overall risk.
risk of COVID-19 case, no change, RR 1.00, p = 1.00, odds ratio converted to relative risk, >50nmol/L, baseline risk approximated with overall risk.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.
Details of all 71 studies
Please send us corrections, updates, or comments.
Submit